title: [Combination therapy of patients with locally advanced breast cancer].
abstract: The investigation involved 30 patients with locally advanced breast cancer (T3-4N1-2M0). Combination therapy comprised two courses: carboplatin 300 mg/m2, i.v., dropwise, on day 1; doxorubicin 30 mg/m2, i.v., bolus-flow, on days 1 and 8; 5-fluorouracil 350 mg/m2, i.v., bolus-flow, on days 1 and 8, and irradiation of the breast and regional metastasis area (single target dose--2 Gy, total target dose--40 Gy). Overall clinical response was 96.7% (29/30), mammography-wise--83.3% (25/30). All patients were found operable and radical mastectomy was performed in 25. Therapeutic effect stage III-IV was histologically confirmed in 40% (25/30), stage I-II--60% (15/25). Median overall and recurrence-free survival was not reached within 36 months in 24/30, relapse-free survival was been reported in 16/24 (66.6%), tumor progression--8/24 (33.4%). Three-year; host-mastectomy recurrence-free survival--68.8 +/- 16.0%.
authors.affiliation: N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
authors.forename: L V
authors.initials: LV
authors.lastname: Manziuk
authors.forename: D V
authors.initials: DV
authors.lastname: Komov
authors.forename: V A
authors.initials: VA
authors.lastname: Khaĭlenko
authors.forename: E V
authors.initials: EV
authors.lastname: Artamonova
authors.forename: Z P
authors.initials: ZP
authors.lastname: Mikhina
authors.forename: V D
authors.initials: VD
authors.lastname: Ermilova
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Abashin
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D016190:Carboplatin / Q000008:administration & dosage; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008327:Mammography; D015409:Mastectomy, Radical; D008875:Middle Aged; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004317:Doxorubicin; D016190:Carboplatin; D005472:Fluorouracil